[HTML][HTML] EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)
A Midha, S Dearden, R McCormack - American journal of cancer …, 2015 - ncbi.nlm.nih.gov
Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in
non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) …
non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) …
Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer
SS Fois, P Paliogiannis, A Zinellu, AG Fois… - International journal of …, 2021 - mdpi.com
Lung cancer is the leading cause of death for malignancy worldwide. Its molecular profiling
has enriched our understanding of cancer initiation and progression and has become …
has enriched our understanding of cancer initiation and progression and has become …
Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of …
NI Lindeman, PT Cagle, DL Aisner… - … of pathology & …, 2018 - meridian.allenpress.com
Context.—In 2013, an evidence-based guideline was published by the College of American
Pathologists, the International Association for the Study of Lung Cancer, and the Association …
Pathologists, the International Association for the Study of Lung Cancer, and the Association …
[HTML][HTML] Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American …
NI Lindeman, PT Cagle, MB Beasley, DA Chitale… - Journal of Thoracic …, 2013 - Elsevier
Objective To establish evidence-based recommendations for the molecular analysis of lung
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …
Establishment of patient-derived non–small cell lung cancer xenografts as models for the identification of predictive biomarkers
I Fichtner, J Rolff, R Soong, J Hoffmann, S Hammer… - Clinical cancer …, 2008 - AACR
Purpose: It was the aim of our study to establish an extensive panel of non-small cell lung
cancer (NSCLC) xenograft models useful for the testing of novel compounds and for the …
cancer (NSCLC) xenograft models useful for the testing of novel compounds and for the …
Cancer genes in lung cancer: racial disparities: are there any?
A El-Telbany, PC Ma - Genes & cancer, 2012 - journals.sagepub.com
Cancer is now known as a disease of genomic alterations. Mutational analysis and
genomics profiling in recent years have advanced the field of lung cancer …
genomics profiling in recent years have advanced the field of lung cancer …
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
Y Pignochino, I Sarotto, C Peraldo-Neia, JY Penachioni… - BMC cancer, 2010 - Springer
Background Advanced biliary tract carcinomas (BTCs) have poor prognosis and limited
therapeutic options. Therefore, it is crucial to combine standard therapies with molecular …
therapeutic options. Therefore, it is crucial to combine standard therapies with molecular …
PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations
This study was aimed to detect the correlation among EGFR/KRAS status and PD-1/PD-L1
expression in non-small-cell lung cancer (NSCLC) patients. PD-1 and PD-L1 expressions …
expression in non-small-cell lung cancer (NSCLC) patients. PD-1 and PD-L1 expressions …
Randomized phase III trial of gefitinib versus docetaxel in non–small cell lung cancer patients who have previously received platinum-based chemotherapy
DH Lee, K Park, JH Kim, JS Lee, SW Shin, JH Kang… - Clinical cancer …, 2010 - AACR
Abstract Purpose: The ISTANA (IRESSA as Second-line Therapy in Advanced NSCLC—
KoreA) study compared gefitinib with docetaxel in patients with advanced or metastatic non …
KoreA) study compared gefitinib with docetaxel in patients with advanced or metastatic non …
Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma
EY Kim, EN Cho, HS Park, JY Hong, S Lim… - Cancer biology & …, 2016 - Taylor & Francis
Compound EGFR mutations, defined as double or multiple mutations in the EGFR tyrosine
kinase domain, are frequently detected with advances in sequencing technology but its …
kinase domain, are frequently detected with advances in sequencing technology but its …